Ironwood Pharmaceuticals, Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021; filed August 5, 2021. Ironwood is a gastrointestinal-focused company whose principal commercial product is LINZESS, marketed in the U.S. with AbbVie and internationally through partners.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Total revenue | $104.0 million | $89.4 million | $192.9 million | $169.4 million |
| Operating income | $65.1 million | $32.7 million | $110.5 million | $45.9 million |
| Operating margin | 62.6% | 36.6% | 57.3% | 27.1% |
| Income before taxes | $54.4 million | $25.2 million | $94.7 million | $28.5 million |
| Income tax benefit | $336.9 million | — | $336.5 million | — |
| Net income | $391.3 million | $25.2 million | $431.2 million | $28.5 million |
| Diluted earnings per share | $2.39 | $0.16 | $2.64 | $0.18 |
| Operating cash flow | Not separately provided for quarter | Not separately provided for quarter | $122.3 million | $63.7 million |
- Collaborative arrangements revenue, primarily Ironwood’s share of U.S. LINZESS profits, rose 16% in Q2 and 17% in the first half year over year. Management attributed growth mainly to higher U.S. prescription demand and inventory fluctuations, partly offset by lower net price.
- At June 30, cash and cash equivalents were $492.7 million, up from $362.6 million at year-end 2020. Cash, cash equivalents and restricted cash totaled $494.9 million. First-half cash increased $130.1 million.
- Convertible-note principal totaled $520.7 million; net carrying value was $442.0 million. Of principal, $120.7 million is due within 12 months, with the 2022 notes maturing June 15, 2022. Six-month interest expense was $15.4 million.
- Current assets were $620.3 million and current liabilities $134.4 million. Stockholders’ equity was $511.8 million, versus $62.6 million at December 31, 2020.
Material changes and unusual items
- The $336.5 million first-half tax benefit was principally a non-cash, discrete $337.8 million benefit from releasing the valuation allowance on most tax attributes and other deferred tax assets. This release drove the unusually high reported net income; pretax income was $94.7 million for the half year.
- First-half R&D expense fell 45% to $27.6 million, primarily due to lower external development spending on IW-3718 after its development was discontinued in 2020. SG&A fell 23% to $54.7 million, mainly from lower employee-related expenses and professional fees.
- First-half API sales fell to $0.8 million from $5.5 million as commercial supply obligations for China transitioned to AstraZeneca in 2020.
- In May 2021, Ironwood and AbbVie settled with Teva, granting a license to market a generic 72 mcg LINZESS, subject to FDA approval, beginning March 31, 2029, barring certain limited circumstances.
- The board authorized up to $150 million in share repurchases through December 31, 2022; no shares had been repurchased under the program by June 30.
Outlook, risks and management commentary
- Management stated that cash on hand was expected to fund projected operating needs for at least the next 12 months. The company also expected to pay $120.7 million of 2022-note principal within that period. No numerical revenue or earnings guidance was provided.
- Ironwood expects continued investment in LINZESS development and its GI pipeline, and substantial commercialization expenses. Management said LINZESS U.S. collaboration revenue is expected to remain a significant share of revenue, but emphasized uncertainty around demand, net pricing, partner expenses, and future cash flows.
- Principal risks include dependence on U.S. LINZESS and AbbVie, competition and reimbursement/pricing pressure, generic-entry and patent-litigation uncertainty, reliance on partners and external manufacturers, product safety and regulatory obligations, and clinical-development risks. COVID-19 could affect promotion, healthcare access, sales, trials and supply, although the filing reported no significant U.S. LINZESS manufacturing or supply disruption to date.
- The company reported that disclosure controls were effective. Leadership changes included Thomas McCourt’s appointment as permanent CEO in June 2021 and the CFO transition effective July 2021.
Investor verification points
- Assess how much earnings growth reflects recurring LINZESS operating performance versus the one-time valuation-allowance release.
- Check U.S. LINZESS demand, net pricing, inventory effects and the allocation of commercialization costs with AbbVie.
- Evaluate the company’s plan and funding for the $120.7 million 2022-note principal maturity, alongside total debt and any conversion or refinancing choices.
- Monitor progress and remaining milestones in the GI pipeline, as well as the effects of discontinued IW-3718 and MD-7246 programs on future spending and growth.
- Track the Teva settlement’s timing and conditions, patent protection, and potential exposure to other generic filings or litigation outcomes.